Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Counsel

• Provided legal support for the company’s drug discovery activities and major corporate alliances
• Negotiated numerous multi-year, sponsored research collaborations with leading academic institutions involving multi-million-dollar research budgets
• Served as Millennium’s primary counselor on evolving issues in the areas of medical privacy and informed consent requirements for research
• Legal representative on business development initiatives to license discovery tools and early stage drug candidates, and to establish and conclude product-specific development programs
  

The Institute for Genomic Research (TIGR) now The J. Craig Venter Institute, one of the first non-profit research centers to incorporate novel technologies in large-scale gene discovery research.

Counsel

• Established key parts of the legal framework for its activities with industry and academia
• Negotiated the terms of early stage research collaborations and agreements covering transfer of materials and confidential information, database access and publication of research results
• Member of the Institute’s Institutional Review Board; helped assure its compliance with applicable regulations and conditions of federal research grants

• Exclusive license agreements with Stanford University, the Broad Institute, Whitehead Institute for Biomedical Research and Dana-Farber Cancer Institute for portfolio companies of a leading venture fund
• Continuing advice to newly founded Institute for Protein Innovation (non-profit) for exchange of materials, collaborative research programs and organizational matters
• Exclusive license agreement with Italian research university and novel technology access agreement with Northwestern University for Lysosomal Therapeutics
• Collaboration and sponsorship agreements for staged research projects among multiple universities and a single disease-focused start-up company with significant federal funding
• Establish core principles and agreement terms for treatment of research results and collaborative research projects for newly established Boston-based non-profit research institute
• Terms for template documents (material transfer, sponsored research and consulting) for multiple start-up companies
• Exclusive license for bioprocessing technology for Alnylam Pharmaceuticals with Massachusetts Institute of Technology
• Exclusive license agreement and sponsored research funding for Alnylam Pharmaceuticals with Mount Sinai School of Medicine
• Exclusive license between the Whitehead Institute for Biomedical Research and new company relating to cell survival technology invented by Howard Hughes Medical Institute investigator
• Consolidation of multiple licenses with predecessor entities into comprehensive amended and restated license agreement for Siamab Therapeutics with University of California - San Diego
• Sponsored research, subcontracts and collaborative research and development agreements (CRADAs) with NIH and defense agencies, universities and companies for clients with novel technologies and funding sources, including government grants and private grant programs. Recent work for AesRx, Antidote Therapeutics, Vedantra Therapeutics, Paratek Pharmaceuticals
• Sponsored research and license agreement with Brown University for Takeda Pharmaceuticals covering research with propriety materials of Takeda, and including specific rights and commercialization terms applicable to results
• Advice with respect to technology access for strategic uses complementing a client’s novel approach to discovery and funding for key research with Columbia University
• Continuing advice to nonprofit Global Alliance for TB drug development on multiple matters for exchanges of materials, including for studies of combination therapies for tuberculosis among multiple parties; standardized documents with hybrid terms covering research and commercialization rights for results among mix of non-profit research entities and industry